Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) CFO David Parrot acquired 2,666 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the acquisition, the chief financial officer owned 1,333 shares of the company’s stock, valued at $19,995. This represents a -200.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Scribe Therapeutics Trading Down 4.4%
NASDAQ:SCTX traded down $0.84 during midday trading on Tuesday, hitting $18.13. 173,852 shares of the company were exchanged, compared to its average volume of 295,836. Scribe Therapeutics Inc. has a fifty-two week low of $17.31 and a fifty-two week high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
